Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. (Nasdaq: CERT),…
CertaraNovember 6, 2024
How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product
Establishing bioequivalence for topical drug products can be challenging and costly, often requiring extensive comparative…
CertaraNovember 5, 2024
Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
The article titled "Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a…
CertaraNovember 4, 2024
FAQs on Developing EMA Policy 0070 Submissions
In September 2023, the European Medicines Agency (EMA) reinstated its Policy 0070 requirement to publish…
CertaraNovember 1, 2024
Improved Translation of Clinical TCE Dosing with Mechanistic Modeling
Abstract: Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…
CertaraOctober 31, 2024
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
Abstract: Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…
CertaraOctober 31, 2024
Guiding Target and Lead Optimization for a Molecular Glue Degrader
Learn how to optimize drug properties for protein degrader therapeutics by exploring system characteristics.
CertaraOctober 31, 2024
